Starting the New Year off right

From the team at FibrosIX Inc, we would like to wish everyone a happy and safe start to 2021!

After a tumultuous 2020, FibrosIX Inc. is ready to move forward in 2021 with the development of our small-molecule therapeutics, to prevent lung fibrosis during chemotherapy or radiotherapy. These therapeutics have a unique mechanism of action, demonstrated efficacy, and a toxicity profile predicted to be superior to clinically approved anti-fibrotics.

In targeting treatment-induced lung fibrosis, FibrosIX is taking advantage of the feasibility and cost-effectiveness of clinical trials. With a standard Phase I trial, and a brief Phase IB/Phase IIA in cancer patients, we expect to have substantially de-risked the technology to the point where efficacy of the compounds in full Phase II trials is assured for investors.

During Q4 of 2020, FibrosIX began to actively engage with potential strategic partners, venture capital and angel investors to finance the research program. In total, we are looking to raise $6.5M to take the program through IND-submission and Phase 1 clinical trials by the end of 2024. The feedback from investors has been positive overall, and FibrosIX is incorporating these comments into our research program. We look forward to continuing these conversations in 2021 as we move forward with our therapeutic development aimed to prevent cancer-treatment induced lung fibrosis.